The truncated somatostatin receptor sst5TMD4 is overexpressed in prostate cancer, where it increases aggressiveness features by regulating key tumor suppressors and oncogenes.
Daniel Hormaechea‐Agulla(Baylor College of Medicine), Raúl M. Luque(Instituto de Salud Carlos III), Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), María M. Moreno(Instituto Maimónides de Investigación Biomédica de Córdoba), Rosa J. Valero, Requena Maria Jose, Michael D. Culler(Ipsen (United States)), Julia Carrasco‐Valiente(Instituto Maimónides de Investigación Biomédica de Córdoba), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), Enrique Gómez‐Gómez(Instituto Maimónides de Investigación Biomédica de Córdoba), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Jimenez-Vacas Juan Manuel
Cited by 0
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Does gut hormone PYY3–36 decrease food intake in rodents?
|Nature|2004|295
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
|Pharmacological Reviews|2018|251
PYY3‐36 as an anti‐obesity drug target
|Obesity Reviews|2005|121